Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
Jul. 11 | ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating | ZD |
Jul. 10 | DexCom, Inc. : A Must-Have Tool for Diabetes Care | ![]() |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses
- The company's enterprise value to sales, at 3.6 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 230B | - | ||
+62.66% | 854B | C+ | ||
+40.42% | 636B | B | ||
-4.37% | 361B | C+ | ||
+17.16% | 324B | B- | ||
+9.87% | 301B | C+ | ||
+15.66% | 247B | B+ | ||
+17.90% | 228B | B- | ||
+14.86% | 177B | C+ | ||
+0.45% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RHO Stock
- Ratings Roche Holding AG